Spencer Strider’s 2026 season is on hold again. The Atlanta Braves announced this week that the right-hander will be shut down from throwing for four weeks because of inflammation in his right elbow.
The news could have been worse. Dr. Keith Meister, the surgeon who handles the Braves’ top arm cases, evaluated Strider’s elbow and found no structural damage. The shutdown is a precautionary measure tied to inflammation that showed up in the imaging after Strider’s exit from Friday’s start against the Mets.
That outing was the alarm bell. Strider was pulled during the fourth inning when his fastball velocity dipped below 90 mph, which for a pitcher who built his career on triple-digit heat is the equivalent of an engine warning light. The MRI on Saturday in Atlanta confirmed inflammation but no ligament damage, which is the result both Strider and the team were praying for.
Here is the plan. Four weeks of no throwing, then a follow-up MRI. If the inflammation has cleared, Strider begins a throwing progression. If it has not, the conversation gets harder.
Meister gave the Braves reason to be optimistic. The doctor told Atlanta that Strider could be activated from the injured list at some point during the regular season’s final two months. The Braves’ realistic best-case is an August return. The realistic worst-case is shutting him down entirely and pointing to 2027.
This is now Strider’s second extended absence in three years. He had elbow surgery in 2024 that cost him most of that season and pushed his return into 2025. He came back, looked good in stretches, and started 2026 with the expectation of being the ace of an Atlanta rotation that needed him desperately.
Then the elbow started barking again. Now the Braves are running through the same playbook they used last time: rest, evaluate, throwing program, rebuild slowly.
The bigger picture for Atlanta is the trade deadline. The Braves are not where they expected to be in the standings. With Strider out, the rotation has been stretched thin, and the team is trying to figure out whether to buy aggressively or stand pat. Bob Nightengale reported this week that the Braves are considered a sleeper for Tigers ace Tarik Skubal, which would be a massive seller-meets-buyer story if it actually happens.
The case for going after Skubal makes more sense without Strider in the rotation. The case against is that giving up two top-10 prospects for a rental ace who is hitting free agency is a steep cost for a team that might not contend anyway.
Strider himself has been measured publicly. He knows the protocol, he has done the rehab work before, and he is not the kind of player who panics on social media. The Braves have made clear that they trust the process, trust Meister, and trust that the inflammation is what the imaging says it is and nothing more.
The thing nobody can fully shake is the velocity drop. When a pitcher who throws 100 mph routinely drops to 89 in the middle of a start, something is wrong even if the MRI looks clean. The inflammation theory checks out, but the body is also reminding everyone that elbows are fragile, that previous surgeries leave scars that show up under stress, and that Strider’s career trajectory is fundamentally different from where it was three years ago.
The Braves need him healthy for the long haul, not just the deadline. If the four-week reevaluation goes well, Atlanta gets a critical piece back for the stretch run. If it does not, the front office has to make trade deadline decisions without one of the most important arms in the franchise’s plans.
Strider will rest. The Braves will wait. The next MRI is the one that matters.
A longtime sports reporter, Carlos Garcia has written about some of the biggest and most notable athletic events of the last 5 years. He has been credentialed to cover MLS, NBA and MLB games all over the United States. His work has been published on Fox Sports, Bleacher Report, AOL and the Washington Post.
